title: Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme.
abstract: DCVax(®) (Northwest Biotherapeutics, Inc., MD, USA) is a platform technology for delivering dendritic cell based therapeutic vaccines for a variety of cancers, including glioblastoma multiforme (GBM). DCVax(®)-L, one of the implementations of the DCVax platform, provides personalized active immunotherapy composed of autologous dendritic cells pulsed with autologous whole tumor lysate. Clinical trials with DCVax-L for GBM included previous Phase I/II clinical trials and an ongoing Phase III trial. Preliminary reports of patient outcomes after administration of the DCVax-L vaccine provide a promising therapeutic paradigm for patients with both initially diagnosed and recurrent GBM. Here we evaluate the current literature and clinical experience with the DCVax platform, with a particular focus on GBM treatment.
authors.affiliation: Department of Neurological Surgery, University Hospitals Case Medical Center & The Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, 2109 Adelbert Road, Cleveland, OH 44106, USA.
authors.forename: Alia
authors.initials: A
authors.lastname: Hdeib
authors.forename: Andrew Edward
authors.initials: AE
authors.lastname: Sloan
mesh_terms: D001932:Brain Neoplasms / Q000628:therapy*; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans
chemical_list: D019496:Cancer Vaccines
keywords: DCVax®; DCVax®-L; dendritic cell immunotherapy; dendritic cell vaccines; glioblastoma multiforme; tumor vaccine